Search

Displaying results 6591 - 6600 of 10000 in total
  1. Drug

    Repinotan

    go.drugbank.com/drugs/DB06506
    Investigational

    Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.

  2. Drug

    Pegvisomant

    go.drugbank.com/drugs/DB00082
    ApprovedInvestigational

    Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediat...

  3. Drug

    Lucatumumab

    go.drugbank.com/drugs/DB06360
    Investigational

  4. Drug

    Xaliproden

    go.drugbank.com/drugs/DB06393
    Investigational

  5. Drug

    Rusalatide

    go.drugbank.com/drugs/DB05309
    Investigational

    TP508 is a non-proteolytic synthetic peptide representing the portion of human thrombin originally identified as the fibroblast high-affinity receptor binding domain.

  6. Drug

    Anpocogin

    go.drugbank.com/drugs/DB06552
    Investigational

    Recombinant nematode anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor (TF)/factor VIIa complex with novel antithrombotic activity.

  7. Drug

    Perifosine

    go.drugbank.com/drugs/DB06641
    Investigational

    Perifosine is a novel alkylphospholipid with antiproliferative properties attributed to protein kinase B inhibition.

  8. Drug

    Ofloxacin

    go.drugbank.com/drugs/DB01165
    ApprovedInvestigational

    A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

  9. Drug

    Inolimomab

    go.drugbank.com/drugs/DB15628
    Investigational

    Inolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease.

  10. Drug

    IN01

    go.drugbank.com/drugs/DB16434
    Experimental

    Of note, the IN01 vaccine is being tested in a Phase I clinical trial in patients with fibrosing interstitial lung disease resulting from SARS-CoV-2 infection (NCT04537130). … The study will explore the effect of this vaccine on pulmonary function, oxygen saturation, quality of life, and fibrosing status in addition to biomarkers and molecular markers of the vaccine.